Transcript for High Yield: Plasma Cell Disorders
High Yield: Plasma Cell Disorders
At the family medicine department, a 70 year old male named Ian came in with progressive fatigue and chronic back pain.
His lab tests show anemia with an MCV of 90. as well as increased calcium, blood urea nitrogen and creatinine levels. Peripheral blood smear showed the following.
Next to Ian, there’s a 65 year old female named Amanda that complains of progressive fatigue, recurrent nosebleeds and blurred vision.
Clinical examination reveals palpable liver and spleen. Her lab tests show anemia with normal MCV, reticulocyte count index over 2%, increased LDH, and a positive Coombs test.
Although their symptoms are very different, both Ian and Amanda have a plasma cell disorder.
Plasma cell disorders are a group of hematological malignancies that are characterized by unregulated proliferation of plasma cells in the bone marrow.
They include multiple myeloma, monoclonal gammopathy of unknown significance or MGUS(em-gus), and Waldenström’s macroglobulinemia.
Each of them produce a monoclonal or M-protein, which is a unique protein of a single type, like a protein “clone”.
Because plasma cells normally make immunoglobulins, it’s not surprising that the M-proteins produced are also immunoglobulins
Alright, now let’s take a closer look at these different plasma cell disorders, starting with multiple myeloma, which is the most common primary bone tumor in people older than 40 to 50 years of age.
In multiple myeloma, the most common M-protein produced is IgG, followed by IgA, and these immunoglobulins have both a heavy and light chain.
More rarely, the myeloma cells can only make the kappa or lambda light chain of the immunoglobulin, and in that situation, the resulting protein is called the Bence-Jones protein.
A high yield concept is the clinical presentation of multiple myeloma, which can be summarized with the mnemonic CRAB (like the animal), “C” is for hypercalcemia, which results from increased osteoclast activity due to the release of osteoclast activating factor from the malignant plasma cells, which resorbs the bone and releases free calcium into the circulation.
Remember that your exam might not just give you the lab finding, but instead give you some symptoms of hypercalcemia, such as abdominal pain, psychiatric changes, constipation or fatigue.
Okay, “R” is for renal disease, which can be caused by multiple mechanisms.
First, the light chains can deposit in and obstruct the renal tubules, and this is called light chain cast nephropathy, or myeloma kidney.
Now, multiple myeloma can also lead to a specific type of amyloidosis called primary amyloidosis.
Here, the immunoglobulin light chains leave the circulation and abnormally aggregate in various tissues, resulting in various clinical manifestations.
These include restrictive cardiomyopathy, a large tongue, also called macroglossia, and nephrotic syndrome to name a few.
So on the exam, beware of primary amyloidosis being a presenting feature of multiple myeloma. “A” is for anemia, which causes fatigue and shortness of breath.
The anemia occurs because the malignant cells infiltrate the bone marrow, and disrupt the normal production of red blood cells.
Finally, “B” is for bone pain, which is due to increased osteoclast activity causing pathologic fractures and lytic bone lesions.
So, in the exams, look for an elderly individual with symptoms of anemia and chronic back pain.
Other manifestations include spinal cord compression if the tumor infiltrates from the vertebrae, and frequent infections, because although the tumor is making lots of immunoglobulins, they are not functional immunoglobulins and so they are not useful in fighting infections.
So for the test remember that a workup for multiple myeloma includes a CBC, which often shows normocytic normochromic anemia, and a peripheral smear, which can show a rouleaux formation due to IgG proteins attaching to red blood cell membranes, and then connecting with other red blood cell membranes, making the red blood cells stick to one other, causing them to look like a stack of coins.
Serum and urine protein electrophoresis, or SPEP(es-pep) and UPEP(you-pep), respectively, are important to see which M protein is predominantly being produced, and is seen as an M-spike.
SPEP detects most multiple myeloma patients that predominantly make IgG, followed by IgA, while UPEP is used to detect the minority of multiple myeloma patients, who only make the Bence-Jones protein.
UPEP is needed because these light chains are rapidly filtered from the blood, so they may not be seen on SPEP.
A urine dipstick is not sufficient, as it only detects albumin.
Also beta-2 microglobulin, a component of the major histocompatibility class 1 antigens found on all nucleated cells, can be shed in the serum.
Serum levels of beta-2 microglobulin are checked in multiple myeloma, because the higher they are, the more severe the disease.
Then, a skeletal radiographic survey should be done to look for “punched out” lytic lesions.
A bone scan should not be obtained, as it only detects osteoblastic lesions, not osteolytic lesions.
- "Robbins Basic Pathology"Elsevier(2017)
- "Harrison's Principles of Internal Medicine, Twentieth Edition (Vol.1 & Vol.2)"McGraw-Hill Education / Medical(2018)
- "Multiple myeloma: 2018 update on diagnosis, risk-stratification, and management"American Journal of Hematology(2018)
- "Multiple Myeloma: An Update"Oman Medical Journal(2013)
- "Multiple Myeloma: Diagnosis and Treatment"Am Fam Physician(2017)
- "Multiple Myeloma: Diagnosis and Treatment"Mayo Clinic Proceedings(2016)
- "Waldenström Macroglobulinemia: Review of Pathogenesis and Management"Clinical Lymphoma Myeloma and Leukemia(2017)
- "Waldenström Macroglobulinemia"Advances In Anatomic Pathology(2012)
- "Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma"International Journal of Laboratory Hematology(2016)